Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Laboratorio Farmaceutico Erfo S.p.A.: Strengths and Weaknesses

Weaknesses: Laboratorio Farmaceutico Erfo S.p.A.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

Laboratorio Farmaceutico Erfo S.p.A. SectorItaly

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Laboratorio Farmaceutico Erfo S.p.A. SectorItaly

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Laboratorio Farmaceutico Erfo S.p.A. SectorItaly

Consensus

Analysts' buy/sell recommendations

-

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

-

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Laboratorio Farmaceutico Erfo S.p.A. SectorItaly

Visibility

-

Analysts' coverage

-

Financial estimates divergence

-

Analysts' recommendations divergence

-

Analysts' Target price divergence

-

Surprise rates

Rating Revisions

Laboratorio Farmaceutico Erfo S.p.A. SectorItaly

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
10.7M - - - - -
1,035B
A
574B
BBB
397B -
AA
- -
324B
AA
281B
A
278B
AAA
193B
A
191B
A
156B
AA
Average 342.99B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ERFO Stock
  4. Ratings Laboratorio Farmaceutico Erfo S.p.A.
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!